Here’s the thing about “99% purity” — it’s technically accurate and practically misleading at the same time. Every peptide vendor slaps this number on their product. But what does it actually mean for your research? And more importantly, what does it NOT mean?
When a lab runs HPLC (high-performance liquid chromatography), they separate all the compounds in a sample. The 99% figure is simple math: the area under the peak that represents your target peptide, divided by the total area of all peaks. If the target peptide peak covers 99% of the chromatogram area, you get 99% purity.
That sounds straightforward. But here’s where researchers get tripped up: 99% purity does NOT mean 99% of the vial is the peptide you ordered. It means 99% of the detectable compounds are the peptide. The other 1% includes synthesis byproducts, truncated sequences, deletion sequences, and residual salts from the purification process.
The impurities aren’t random. They’re predictable byproducts of solid-phase peptide synthesis:
A 1% deletion sequence — one amino acid missing in a 30-amino-acid peptide — can have completely different biological activity. In some cases, these truncated or deletion peptides can be antagonists rather than agonists. They can block the receptor your target peptide is supposed to activate.
I’ve seen researchers waste months troubleshooting their data only to discover that a low-quality peptide batch was producing conflicting results. The “99% purity” number on the label didn’t capture the one deletion sequence that was throwing off their entire study.
Don’t trust the number on the website. Ask for the Certificate of Analysis (COA) and look at the actual HPLC chromatogram. A good COA shows:
If a vendor won’t provide the chromatogram, that’s a red flag. The number “99%” is meaningless without seeing the peaks.
Learn how to read a peptide COA to verify what you’re actually getting before it goes into your research protocol.
This is the question we get most often, and the answer is more nuanced than most people expect. The legal status of peptides depends on what you’re doing with them, where you are, and how you’re sourcing them.
In the United States and most Western countries, peptides are legal to purchase for research purposes. They’re classified as research chemicals, not controlled substances or prescription medications. This means they can be sold to qualified researchers, laboratories, and institutions for experimental use.
The key phrase is “for research purposes.” This is not a loophole — it’s a legitimate regulatory category. Research chemicals are distinct from drugs, supplements, and cosmetics. They exist in a regulatory space that allows scientific investigation without requiring the same approval process as pharmaceuticals.
No. Research peptides are explicitly not approved for human consumption, medical treatment, or dietary supplementation. They have not been evaluated by the FDA for safety, efficacy, or purity standards required for human use.
When you see “for research only” on a peptide label, that’s a legal requirement, not a suggestion. The vendor is required to state that the product is not for human consumption. The researcher is required to use it only in laboratory settings.
This labeling requirement means:
Some peptides are subject to additional regulation. Growth hormone-related peptides may fall under different rules in certain jurisdictions. Import regulations vary by country — some nations restrict peptide importation more than others.
Always check local regulations before purchasing or importing peptides. The rules in the United States are different from the rules in Canada, the UK, Australia, and other countries. If you’re conducting research outside the US, verify your local compliance requirements.
For research compliance, maintain these records:
Good documentation isn’t just for compliance — it protects you if questions arise. Most research institutions require this documentation as part of their standard operating procedures.
Disclaimer: This information is for educational purposes only. It does not constitute legal advice. Consult a qualified legal professional for guidance specific to your jurisdiction and research situation.
Dosing is where most research protocols go wrong. Not because the math is hard — it’s not. But because researchers skip the calculation step and estimate. Estimation leads to inconsistency, and inconsistency ruins data.
This guide covers the practical side of peptide dosing: units, measurement, common ranges, and the calculation techniques that prevent errors.
Peptide dosing uses three units, and confusing them is the most common mistake:
Concentration is the bridge between these units: mg/mL after reconstitution. This tells you how much peptide is in each milliliter of liquid.
These ranges are based on published studies and animal model research. They’re starting points, not universal rules:
Concentration = Total Peptide (mg) ÷ Solvent Volume (mL)
Example: 5mg peptide in 2mL water = 2.5mg/mL = 2500mcg/mL
Once you know concentration, dose calculation is simple:
Dose Volume (mL) = Desired Dose (mcg) ÷ Concentration (mcg/mL)
Example: You want 500mcg. Your concentration is 2500mcg/mL. Volume = 500 ÷ 2500 = 0.2mL
That’s it. Two equations. If you can do this math, you can dose any peptide accurately.
Use our peptide calculator if you want to skip the manual calculation. It does the same math but faster and without error risk.
All peptide research should follow institutional guidelines. Peptides are research tools, not approved therapeutics. Document your protocols, maintain batch records, and dispose of materials properly.
Single-peptide research is the standard, but it’s not always the whole picture. Biological systems don’t work in isolation. Multiple pathways interact, and sometimes you need to study the interaction, not just the individual components.
That’s where peptide blends come in. A blend isn’t just a marketing gimmick — it’s a research tool designed to study synergistic effects, complementary mechanisms, and compound pathways.
Most published research starts with single compounds. You establish a baseline, understand the mechanism, and then introduce complexity. Blends are the next step after you understand the individual components.
Researchers study blends for three reasons:
KLOW combines three distinct mechanisms. Kisspeptin is studied for reproductive hormone signaling (GnRH release). MOTS-c is a mitochondrial-derived peptide that regulates metabolic function. Oxytocin is a neuropeptide with roles in social bonding, stress response, and cellular signaling.
The combination is interesting because these three pathways rarely interact in standard research. KLOW allows researchers to study whether metabolic regulation, reproductive signaling, and social/stress pathways have cross-talk effects.
GLOW focuses on skin health, tissue repair, and metabolic function. GHK-Cu is the primary copper-binding peptide for collagen synthesis research. Oxytocin and MOTS-c add secondary mechanisms that may influence tissue remodeling and cellular energy.
This blend is designed for dermatological and wound healing research. The three components don’t overlap in mechanism, which makes them ideal for studying multi-pathway tissue repair.
This is the classic growth hormone research stack. CJC-1295 is a GHRH analog that stimulates the hypothalamus. Ipamorelin is a GHRP mimetic that acts on the pituitary. Together they create a more complete growth hormone release profile than either alone.
This isn’t a random combination. The two mechanisms are well-documented to work together: CJC-1295 provides the signal, Ipamorelin amplifies the response. Researchers studying GH release patterns almost always use both.
Start with your research question. Don’t choose a blend because it sounds impressive; choose it because the components address your specific research needs.
Always verify that each component in the blend has been independently tested. A blend is only as good as its weakest component. Read the COA for each peptide before starting your protocol.
Read our full peptide blends guide for more detailed information on each blend and its research applications.
I’ve lost peptides to bad storage. It happens to every researcher eventually. You get distracted, leave a vial on the bench overnight, or forget to label the reconstitution date. The next morning, the solution is cloudy, the color is off, and you just wasted $150.
Storage isn’t exciting, but it’s the difference between reliable data and wasted experiments. Here’s what actually works.
Peptide powder is remarkably stable. Most lyophilized peptides last 12-24 months when stored properly. The key enemies are moisture, heat, and light — in that order.
Temperature: Store at -20°C (your standard freezer) for maximum stability. If you’re using the peptide within 3 months, 2-8°C (refrigerator) is fine. But don’t leave it at room temperature for more than a few days. Heat accelerates degradation exponentially.
Moisture: This is the big one. Lyophilized peptides are essentially freeze-dried, and they want to rehydrate. If moisture gets in, the peptide starts reacting with itself. Store in a sealed container with a desiccant packet. Don’t open the vial in humid environments.
Light: UV light breaks peptide bonds. Store in amber vials or keep the vial in its original packaging. A drawer is fine; a windowsill is not.
Once you add water, the clock starts. The peptide is now in an aqueous environment, and chemical reactions begin. Here’s how long you actually have:
Learn to recognize the warning signs:
Storage isn’t complicated. It’s discipline. Follow these rules, and your peptides will last as long as they’re supposed to. Ignore them, and you’ll lose money and data.
The first time I reconstituted a peptide, I stared at the vial for five minutes wondering if I was about to ruin a $200 compound. The powder looked expensive. The bacteriostatic water looked harmless. The combination felt like a chemistry experiment I wasn’t qualified for.
Here’s the truth: reconstitution isn’t hard. It’s just a process that feels intimidating until you’ve done it once. This guide breaks it down into steps that anyone can follow, even if you’ve never held a research syringe before.
Don’t overcomplicate the setup. You need four things:
Before you touch anything, figure out your concentration. Most peptides come in 2mg, 5mg, or 10mg vials. A standard starting dilution is 2mL of bacteriostatic water per 5mg of peptide. That gives you 2.5mg/mL, or 2500mcg/mL.
Why 2mL? It’s the sweet spot. Enough volume to dissolve the peptide completely, not so much that you’re injecting large amounts of liquid. If you use 1mL for 5mg, you get 5mg/mL — very concentrated, harder to draw accurately. If you use 5mL for 5mg, you get 1mg/mL — too dilute for most research applications.
Wipe the rubber stopper with an alcohol swab. Don’t touch it after cleaning. Don’t blow on it. Don’t set it down on a dirty surface. The stopper is the entry point for contamination, so treat it like the sterile field it is.
Draw your calculated volume of bacteriostatic water into the syringe. Remove the needle cap. Insert the needle through the center of the rubber stopper — the center is the thinnest part and creates the cleanest puncture.
Here’s the critical part: inject the water SLOWLY down the inside wall of the vial. Don’t spray it onto the powder. Let the water run down the glass and pool at the bottom. The powder will absorb it naturally. This prevents foaming and denaturation.
Do NOT shake the vial. I repeat: do not shake it. Shaking creates shear forces that can break peptide bonds. Instead, gently swirl the vial or roll it between your palms. The peptide will dissolve in 30-60 seconds. Some peptides (like BPC-157) dissolve instantly. Others (like GHK-Cu) may need a minute of gentle swirling.
If the solution is cloudy or has particles, it’s not fully dissolved. Keep gently swirling. If it still doesn’t clear after 2 minutes, you may have used the wrong solvent or the peptide is degraded.
Write the peptide name, concentration, and reconstitution date on the vial. Use a permanent marker. Store in the refrigerator at 2-8°C. Most reconstituted peptides are stable for 2-4 weeks refrigerated. If you need longer storage, aliquot into smaller volumes and freeze at -20°C.
That’s it. Reconstitution is a five-step process that takes five minutes. The first time feels intimidating; the tenth time is routine. Follow these steps, and you’ll get consistent results every time.
When you see “99% purity” on a peptide product, what does that number actually represent? For researchers, purity is not just a marketing claim — it is a critical quality metric that affects the reliability of your experimental results.
Purity percentage refers to the proportion of the target peptide sequence in the sample compared to impurities. A 99% pure peptide means that 99% of the material is the exact sequence you ordered, while the remaining 1% consists of related compounds, synthesis byproducts, and residual solvents.
High-performance liquid chromatography (HPLC) is the gold standard for purity testing. The sample is run through a chromatography column, and the resulting chromatogram shows peaks for each compound present. The area under the target peptide peak divided by the total area gives the purity percentage.
Impurities can interfere with experimental results. Related peptide sequences (deletion peptides, truncated peptides, or sequences with single amino acid substitutions) may have different biological activities. Even small amounts of these contaminants can skew dose-response curves or produce unexpected effects.
The remaining 1% typically includes:
Always request a Certificate of Analysis (COA) from your supplier. The COA should include:
Learn how to read a peptide COA to verify your peptide quality.
Let’s be honest — walking into peptide research for the first time feels like staring at a menu in a foreign language. BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu… the names alone are enough to make your head spin. And every vendor claims their product is the one you need.
So how do you actually choose? Not by reading marketing copy. You choose by understanding what your research is trying to answer, then matching the mechanism to the question.
Most researchers who reach out to us aren’t asking “which peptide is best?” — they’re asking “I need to study [X], what’s the standard compound for that?” That’s the right approach. Peptides are tools. You don’t buy a hammer because you like hammers; you buy it because you need to drive nails.
Go with BPC-157 or TB-500. BPC-157 is the body protection compound derived from gastric juice — nature’s own repair signal. TB-500 (thymosin beta-4 fragment) is what cells use to migrate and rebuild. Most tissue repair studies use one or both. BPC-157 tends to be the starting point for soft tissue work; TB-500 gets added when you’re looking at systemic migration patterns.
Tirzepatide and GLP-3RT are where the metabolic research is happening right now. Tirzepatide hits both GLP-1 and GIP receptors — dual pathway. If you’re studying appetite regulation, blood sugar control, or energy metabolism, these are your compounds. Don’t overthink it; start with the mechanism that matches your study design.
Semax is the Russian-developed synthetic peptide derived from ACTH 4-10. It’s been studied for BDNF expression, cognitive enhancement, and neuroprotection. If your research involves brain-derived neurotrophic factor or stress response in neural tissue, Semax is the standard compound. It pairs well with BDNF assays.
GHK-Cu is the copper-binding peptide that drives collagen synthesis. It’s not new; it’s been studied for decades in wound healing and skin remodeling. If your research involves dermal fibroblasts, extracellular matrix, or tissue regeneration, GHK-Cu is the baseline compound. It’s also the most forgiving peptide for new researchers — stable, well-documented, and easy to work with.
Here’s what I tell every new researcher: start with one compound, master it, then add complexity. Don’t begin with a three-peptide blend. Don’t try to compare five mechanisms at once. Pick the peptide that most directly answers your primary research question, run a clean protocol, and establish your baseline data.
Once you have that foundation, you can layer in comparisons, blends, or dose-response curves. But the mistake most new researchers make is overcomplicating the study design before they understand the variables.
Still not sure? Here’s the one-sentence version:
Use our peptide calculator to figure out reconstitution and dosing once you’ve picked your compound. And if you’re still stuck, reach out — we actually read the research and can point you in the right direction based on what you’re studying, not what we’re trying to sell.
One of the most common questions in peptide research is also one of the hardest to answer cleanly: how long until you observe measurable changes? The honest answer is that it depends entirely on the compound, the endpoint being measured, and the biological system under study. Here’s what the published preclinical literature says about timelines for each major compound category.
Peptides operate through different mechanisms, and different biological processes change at different rates. Acute inflammatory responses can shift within days. Collagen synthesis and tissue remodeling take weeks. Metabolic markers — insulin sensitivity, fasting glucose, lipid profiles — require months of study to show statistically significant changes. Comparing timelines across compound categories without accounting for mechanism is like asking how long it takes to “see results” from taking aspirin vs. statins. Different tools, different timescales.
BPC-157 is among the most studied tissue repair peptides in rodent models. Tendon and ligament repair studies typically show measurable histological changes at 2–4 weeks. Gastric mucosal healing studies show acute responses within days. The compound’s mechanism — upregulation of growth hormone receptors and nitric oxide synthesis — is fast-acting at a cellular level, which is reflected in the relatively short study windows used in published research.
TB-500 (Thymosin Beta-4) operates partly through actin regulation and cell migration — processes that are somewhat slower. Wound healing studies typically observe significant differences at 3–5 weeks. Studies examining cardiac tissue outcomes extend to 8 weeks or longer.
GIP/GLP-1 agonists like Tirzepatide and the triple agonist Retatrutide work through receptor signaling that affects satiety, insulin secretion, and energy expenditure. Early metabolic marker changes (insulin sensitivity, postprandial glucose) can appear within 2–4 weeks in animal models. Meaningful body composition changes in rodent studies typically require 8–16 weeks of continuous administration. Human clinical trial data for these compounds follows similar timescales — the Phase 2 Retatrutide trials ran 24 weeks for primary endpoints.
Semax‘s BDNF-upregulating effects appear relatively quickly in animal models — cognitive performance assessments in rodent studies show differences within 10–14 days of administration. Neuroprotective effects following ischemic models are assessed acutely (24–72 hours post-event) as well as at 7–14 day endpoints.
Epithalon‘s longevity-oriented mechanisms (telomerase activation, circadian rhythm normalization) operate on longer timescales. Published studies examining telomere parameters in aged animals run 10-day courses over months, with assessments at 3–6 month intervals.
NAD+ precursor research typically measures mitochondrial markers, NAD+/NADH ratios, and age-related biomarkers at 4–8 week intervals. MOTS-c metabolic studies in animal models show AMPK activation markers within 2 weeks, with downstream metabolic effects assessed at 4–6 weeks.
Across every compound category, the largest source of inconsistent research outcomes isn’t the compound — it’s preparation variability. An incorrectly reconstituted vial delivers inconsistent dosing across a study period. Use the CoreVionRX reconstitution calculator to standardize your volumes from day one. Store compounds per the Peptide Storage Guide to maintain stability across the full study window.
All information is for laboratory research purposes only. CoreVionRX compounds are not intended for human use, diagnosis, or treatment.
In preclinical peptide research, a cycle refers to a structured period of compound administration followed by a deliberate off-period. The concept mirrors pharmaceutical study design: continuous, unstructured exposure makes it difficult to isolate variables, observe dose-response relationships, or assess how a subject responds after a rest interval. Structured cycles produce cleaner data.
This isn’t about chasing effects. It’s about research discipline — the same discipline that makes your BPC-157 or TB-500 data replicable across study periods.
Different compound classes show different research windows based on their mechanisms and published preclinical literature.
Research protocols in this category most commonly run 4–8 weeks. Both BPC-157 and TB-500 have been studied over short intensive windows in animal models — typically 2–4 weeks for acute studies and up to 8 weeks for chronic tissue remodeling assessments. GHK-Cu research often extends to 8–12 weeks given its role in collagen synthesis and slow-turnover tissue processes.
Tirzepatide and Retatrutide research typically follows longer observation windows — 8–16 weeks minimum in published literature — because metabolic markers (insulin sensitivity, lipid profiles, body composition) change slowly. Shorter cycles produce insufficient data to draw conclusions about glycemic or metabolic outcomes.
Semax studies in rodent models commonly run 10–20 days in acute protocols, with some chronic neuroregeneration studies extending to 30 days. Epithalon longevity research has been studied in 10-day courses, often with multiple courses per year in the published literature.
Off-periods serve three purposes in good research design: they provide a washout window to assess persistence of observed effects, they allow receptor sensitivity to normalize (relevant to GHRH analogs like CJC-1295 and Ipamorelin), and they create a natural comparison baseline for the next study period.
For most compound categories, an off-period equal to the cycle length is a reasonable starting structure. A 6-week tissue repair cycle warrants a 4–6 week off-period before resuming.
Multi-compound research — studying more than one peptide simultaneously — introduces additional variables. If you’re studying a blend like GLOW (GHK-Cu + BPC-157 + TB-500), the cycle structure is determined by the component with the shortest published study window. Introducing compounds mid-cycle compromises data integrity; changes should align with cycle start dates.
The most common source of inconsistent peptide research data isn’t the compound — it’s inconsistent preparation. Use the CoreVionRX peptide reconstitution calculator to standardize your dilution volumes across cycles. Store compounds per the Peptide Storage Guide to maintain stability between study periods.
All information is for laboratory research purposes only. CoreVionRX compounds are not intended for human use, diagnosis, or treatment.